why choose us

First received: March 24, 2023

Clinical Trial: PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Castration-Resistant Prostate Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1b Study Evaluating Combinations With PSCA-Targeting Chimeric Antigen Receptor (CAR)-T Cells for Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

Brief Summary: This phase Ib trial tests the safety, side effects, and best dose of autologous anti-prostate stem cell antigen (PSCA)-chimeric antigen receptor (CAR)-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (PSCA-CAR T cells), plus or minus radiation, in treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic).Castration-resistant prostate cancer continues to grow and spread despite the surgical removal of the testes…

Read more